Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

763.06 +14.35 (+1.92%)

Streaming Delayed Price Updated: 11:35 AM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

58 59 Next >

Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation

July 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗

July 30, 2024

Via Benzinga

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

Bull Market Buys: 2 Growth Stocks to Own for the Long Run ↗

July 27, 2024

These companies are no strangers to beating the market.

Via The Motley Fool

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand ↗

July 25, 2024

Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.

Via Benzinga

$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today ↗

July 22, 2024

Via Benzinga

Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗

July 19, 2024

Via Benzinga

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗

July 16, 2024

Via Benzinga

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients ↗

July 23, 2024

MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six...

Via Benzinga

Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst ↗

July 18, 2024

Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth.

Via Benzinga

3 Standout Stocks to Buy for the Next Bull Market ↗

July 18, 2024

These standout stocks to buy for a bull market offer promising potential for significant gains as market conditions continue to strengthen.

Via InvestorPlace

Stocks to Buy: 7 Founder-Led Companies Set to Outperform ↗

July 17, 2024

These founder-led companies are at the forefront of industry innovation, and historical trends indicate that they will likely outperform.

Via InvestorPlace

The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals ↗

July 11, 2024

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today ↗

July 04, 2024

Via Benzinga

Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗

July 02, 2024

Via Benzinga

CPI Data Sparks Rally in Biotech Stocks

July 15, 2024

Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.

Via MarketBeat

Topics ETFs Economy

Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling ↗

July 15, 2024

Via Benzinga

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗

July 15, 2024

Revenue is climbing at these two drug companies -- and the trend should continue.

Via The Motley Fool

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 ↗

July 09, 2024

Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.

Via InvestorPlace

Healthcare Stocks Continue To Lag The Market-Can Anything Help ? ↗

July 08, 2024

Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health.

Via Talk Markets

3 No-Brainer Stocks to Buy in July ↗

July 08, 2024

Investors shouldn't have to think too hard about these great stocks.

Via The Motley Fool

3 Pharma Stocks Already Ushering in the Next Biotech Boom ↗

July 08, 2024

So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.

Via InvestorPlace

The 3 Best Biotech Stocks to Buy in July 2024 ↗

July 05, 2024

For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.

Via InvestorPlace

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗

July 05, 2024

A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.

Via Investor's Business Daily

7 High Priced Stocks That Would Benefit From a Stock Split ↗

July 04, 2024

These companies are prime stock split candidates following moves from Nvidia and Broadcom along with other big names.

Via InvestorPlace

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data ↗

July 03, 2024

EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a...

Via Benzinga

Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD

July 03, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

What's Going On With Regeneron Pharmaceuticals Stock On Friday? ↗

June 28, 2024

Regeneron Pharmaceuticals received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for conditional approval of odronextamab. Final decision...

Via Benzinga

Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

June 28, 2024

Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell...

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

June 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today